#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Asthma Dermatitis atopic Dementia Alzheimer's type Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Focal segmental glomerulosclerosis Mycobacterium abscessus infection Cerebral haemorrhage Wiskott-Aldrich syndrome Anti-HLA antibody test positive Complex regional pain syndrome Essential thrombocythaemia Ewing's sarcoma metastatic Spinal cord injury cervical Chronic myeloid leukaemia Myeloproliferative neoplasm Head and neck cancer Malignant central nervous system neoplasm Synovial sarcoma recurrent Adrenogenital syndrome More trials…

    Learn about Rare Diseases

    Lymphangiosarcoma – Life with Disease Alternating hemiplegia of childhood – Basic Information Leiomyosarcoma – Trials in Disease Erdheim-Chester disease – Trials in Disease Shprintzen-Goldberg syndrome – Treatment Lymphangioma – Basic Information Andersen-Tawil syndrome – Diagnostics Rett syndrome – Diagnostics Myelodysplastic syndrome with excess blasts – Basic Information Isodicentric chromosome 15 syndrome – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Potassium Chloride Modafinil Calcitriol Remifentanil Hydrochloride GSKVX000000030918 Miglustat Tazobactam Sodium CAL101 Crinecerfont Asparaginase Bisoprolol Fumarate Gen1055 Trastuzumab Izaflortaucipir (18F) Human Serum Albumin 5% Cemiplimab Hydroxychloroquine Sulfate Meropenem Phenprocoumon Piperacillin Monohydrate More therapies…

    Learn about Your Condition

    Chronic disease Sickle cell anaemia Craniopharyngioma Osteoporosis Thymoma Endometriosis Adenomatous polyposis coli Peyronie's disease Clostridium difficile colitis Rectal neoplasm Hyperthyroidism Ehlers-Danlos syndrome Colitis Lymphatic malformation COVID-19 More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Wojewódzki Szpital Specjalistyczny nr 5 im. św. Barbary…

Wojewódzki Szpital Specjalistyczny nr 5 im. św. Barbary w Sosnowcu

Pl. Medykow 1, Sosnowiec, 41-200, Poland

Want to learn more about this study or check if you can participate? Contact us.

  • Study of Pembrolizumab Combined with Standard Chemo-Radiotherapy for Newly Diagnosed Glioblastoma Multiforme Patients

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Pembrolizumab
    Poland

  • Study on the Effectiveness of Infliximab, Ustekinumab, and Vedolizumab for Patients with Resistant Crohn’s Disease

    Recruiting

    2 1 1 1 1
    Investigated Drugs:
    • Ustekinumab
    • Infliximab
    • Vedolizumab
    Poland

  • Study on the Effectiveness of Infliximab, Tofacitinib, and Vedolizumab in Patients with Ulcerative Colitis Resistant to Initial Treatment

    Recruiting

    2 1 1 1 1
    Investigated Drugs:
    • Tofacitinib
    • Infliximab
    • Vedolizumab
    Poland

  • Study of anifrolumab effectiveness compared to placebo in adults aged 18-70 with systemic sclerosis

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Anifrolumab
    Austria Belgium France Germany Hungary Italy +4

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!